BioNTech (NASDAQ:BNTX) Lifted to “Neutral” at JPMorgan Chase & Co.
JPMorgan Chase & Co. upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from an underweight rating to a neutral rating in a report released on Monday morning, MarketBeat.com reports. They currently have $125.00 target price on the stock, up from their previous target price of $91.00. A number of other equities analysts also recently commented […]
19 Sep 06:02 · The Markets Daily